���ϳԹ���Դ

Katrin´s research focuses on the development of immunocompetent patient-derived xenograft (PDX) models of ovarian carcinomas to improve therapeutic interventions through novel immune therapies and targeted fluorescence image-guided surgery. These advanced mouse models are additionally reconstituted with a functional human immune system, which replicate the heterogeneities observed in patient tumours whilst also reproducing key features of the human immune system. Immunotherapies, neither immune-checkpoint inhibitor nor chimeric antigen receptor (CAR) T cells, have been shown successful in ovarian carcinomas, yet. Key drivers for her project are the genomic and phenotypic characterization of her established PDX models including the verification of the genomic fidelity to the paired primary tumors as well as the phenotypic deciphering of the complex tumor microenvironment (TME). The aim of Katrin´s project is to provide a good and reliable preclinical animal model that combines the interactions of the TME, including human immune system and genomic evolution of tumor cells.

2017

2022

2021

2020

2019

2024

2026

2025

2023

1.         Kleinmanns, K., K. Bischof, S. Anandan, M. Popa, L.A. Akslen, V. Fosse, I.T. Karlsen, B.T. Gjertsen, L. Bjørge, and E. McCormack, CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine, 2020. 56.

2.         Kleinmanns, K., V. Fosse, B. Davidson, E.G. de Jalón, O. Tenstad, L. Bjørge, and E. McCormack, CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine, 2020. 56.

3.         Kleinmanns, K., V. Fosse, L. Bjørge and E. McCormack, The emerging role of cd24 in cancer theranostics—a novel target for fluorescence image-guided surgery in ovarian cancer and beyond. Journal of Personalized Medicine, 2020. 10(4): p. 255.

4.         Anandan, S., L.C.V. Thomsen, S.-E. Gullaksen, T. Abdelaal, K. Kleinmanns, J. Skavland, G. Bredholt, B.T. Gjertsen, E. McCormack, and L. Bjørge, Phenotypic characterization by mass cytometry of the microenvironment in ovarian cancer and impact of tumor dissociation methods. Cancers, 2021. 13(4): p. 755.

5.         Kleinmanns, K., S.-E. Gullaksen, G. Bredholt, B. Davidson, C.F. Torkildsen, S. Grindheim, L. Bjørge, and E. McCormack, Humanized ovarian cancer patient-derived xenografts for improved preclinical evaluation of immunotherapies. Cancers, 2022. 14(13): p. 3092.

6.         Kleinmanns, K., C.H. Gjerde, A. Langer, V. Fosse, E.G. de Jalón, C. Leitch, M. Popa, P. Gelebart, and E. McCormack, Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. Biomarkers of the Tumor Microenvironment, 2022: p. 329-344.

7.         Popa, M., V. Fosse, K. Kleinmanns, L. Bjørge and E. McCormack, Xenograft Models of Ovarian Cancer for Therapy Evaluation, in Ovarian Cancer. 2022, Springer. p. 275-293.

8.         Perrone, M.G., P. Vitale, M. Miciaccia, S. Ferorelli, A. Centonze, R. Solidoro, C. Munzone, C. Bonaccorso, C.G. Fortuna, and K. Kleinmanns, Fluorochrome selection for imaging intraoperative ovarian cancer probes. Pharmaceuticals, 2022. 15(6): p. 668.

9.         García de Jalón, E*., K. Kleinmanns*, V. Fosse, B. Davidson, L. Bjørge, B.E. Haug, and E. McCormack, Comparison of five near-infrared fluorescent folate conjugates in an ovarian cancer model. Molecular Imaging and Biology, 2023. 25(1): p. 144-155.

10.       Thomsen, L.C.V., K. Kleinmanns, S. Anandan, S.-E. Gullaksen, T. Abdelaal, G.A. Iversen, L.A. Akslen, E. McCormack, and L. Bjørge, Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study. Cancers, 2023. 15(20): p. 5106.

11.       Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, et al. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16. Journal for Immunotherapy of Cancer. 2024;12(4).

12.       Torkildsen CF, Austdal M, Jarmund AH, Kleinmanns K, Lamark EK, Nilsen EB, et al. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients. Frontiers in Immunology. 2024;15:1394497.

13.       Kleinmanns K, Bjørge L. Enhancing precision oncology in high-grade serous carcinoma: the emerging role of antibody-based therapies. npj Women's Health. 2024;2(1):7.

14.       Tandaric L, Auranen A, Kleinmanns K, DePont Christensen R, Vestrheim Thomsen LC, Wogsland CE, et al. Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD 73/anti‐PD‐L 1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV 30 trial. Molecular Oncology. 2025;19(5):1436-51.

15.       Gjerde CH, Kleinmanns K, Langer A, Ponce GRdG, Rozmus E, Stangeland GN, et al. A 3D ovarian cancer metastasis model using a decellularized peritoneal matrix to study therapy response. EBioMedicine 124 (2026)

16.       Tandaric L, Bjorge L, Rott Lode M, Fredvik Torkildsen C, Aehnlich P, Elnour R, et al. Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy. bioRxiv. 2025:2025.08. 08.669244. (accepted, Last author)